NEI
VRTX icon

Northwest & Ethical Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Northwest & Ethical Investments’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.31M Sell
6,664
-5,278
-44% -$2.34M 0.08% 167
2026
Q1 		$5.33M Buy
11,942
+838
+8% +$391K 0.12% 158
2025
Q4 		$5.03M Sell
11,104
-4,211
-27% -$1.82M 0.11% 171
2025
Q3 		$6M Buy
15,315
+226
+1% +$94.5K 0.14% 164
2025
Q2 		$6.72M Buy
15,089
+530
+4% +$244K 0.17% 156
2025
Q1 		$7.06M Sell
14,559
-13,263
-48% -$6.18M 0.19% 146
2024
Q4 		$11.2M Buy
27,822
+1,182
+4% +$548K 0.3% 106
2024
Q3 		$12.4M Buy
26,640
+2,596
+11% +$1.25M 0.33% 105
2024
Q2 		$11.3M Hold
24,044
– – 0.32% 103
2024
Q1 		$10.1M Sell
24,044
-18,810
-44% -$7.95M 0.29% 114
2023
Q4 		$17.4M Buy
42,854
+4,339
+11% +$1.6M 0.54% 58
2023
Q3 		$13.4M Buy
38,515
+16,818
+78% +$5.88M 0.45% 74
2023
Q2 		$7.64M Buy
21,697
+5,803
+37% +$1.96M 0.24% 129
2023
Q1 		$5.01M Buy
15,894
+11,530
+264% +$3.46M 0.17% 173
2022
Q4 		$1.26M Sell
4,364
-8,790
-67% -$2.68M 0.04% 279
2022
Q3 		$3.81M Sell
13,154
-361
-3% -$104K 0.15% 181
2022
Q2 		$3.81M Hold
13,515
– – 0.14% 178
2022
Q1 		$3.53M Sell
13,515
-8,126
-38% -$1.93M 0.11% 205
2021
Q4 		$4.75M Buy
+21,641
New +$4.21M 0.14% 169
2021
Q2 		– Sell
-6,566
Closed -$1.41M – 434
2021
Q1 		$1.41M Buy
6,566
+3,943
+150% +$866K 0.05% 305
2020
Q4 		$620K Buy
+2,623
New +$602K 0.02% 348

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Northwest & Ethical Investments's VRTX Position: Q2 2026 in Review

Northwest & Ethical Investments reduced its Vertex Pharmaceuticals (VRTX) stake by 44% in Q2 2026, selling an estimated $2.34M and leaving 6,664 shares worth $3.31M. The position accounts for 0.08% of the portfolio, ranked #167.

Northwest & Ethical Investments first reported a position in VRTX in Q4 2020 and has held it in 21 quarters since. The position peaked at $17.4M in Q4 2023. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Northwest & Ethical Investments held 6,664 shares of Vertex Pharmaceuticals worth $3.31M as of Q2 2026.
  • Northwest & Ethical Investments sold 5,278 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.34M.
  • Vertex Pharmaceuticals made up 0.08% of Northwest & Ethical Investments's portfolio in Q2 2026, its #167 holding.
  • Northwest & Ethical Investments first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 21 quarters since.
  • Northwest & Ethical Investments's Vertex Pharmaceuticals position peaked at $17.4M in Q4 2023.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Northwest & Ethical Investments's 13F filing for Q2 2026, filed 13 Aug 2026.